The 10 to Watch
1) OA10.01 — Dato-DXd in NSCLC brain mets (TROPION-Lung01 post-hoc)
Signal: Intracranial activity vs docetaxel.
Key data: iORR 37.5% (6/16) with Dato-DXd vs 0% (0/11); untreated brain mets iPFS HR 0.48; responses NSq only; median time to response 1.5 mo.
Why it matters: Clinically relevant CNS activity from an ADC — an area of unmet need.
2) OA06.02 — QLC5508 (B7-H3 ADC) in previously treated ES-SCLC (Phase 1 update)
Signal: Manageable safety with OS ~11–12 mo in heavily pretreated SCLC.
Key data: Median PFS ~5.5–6.0 mo; OS ~11.5–11.7 mo; ≥G3 neutropenia 17%, WBC ↓ 10%; ILD-related discontinuations rare.
Why it matters: Adds to B7-H3 ADC momentum in a tough setting.
3) OA06.04 — ABBV-706 (SEZ6-targeting ADC) in R/R SCLC (dose optimization)
Signal: Promising efficacy, cleaner at 1.8 mg/kg Q3W (RP2D).
Key data: Higher ORR in Top1i-naïve and 2L (up to 62–81%); longer DOR/PFS at 1.8 mg/kg; ≥G3 anemia 39% (1.8 mg/kg) vs 62% (2.5 mg/kg); ILD adjudicated 9%.
Why it matters: Another ADC with traction in SCLC, dose clarity helps.
4) OA02.02 — NeoADAURA MRD analysis (neoadjuvant osimertinib ± chemo)
Signal: ctDNA-MRD is prognostic and treatment-responsive.
Key data: Baseline MRD- vs MRD+ EFS HR 0.24; pre-surgery MRD+ fell to 23% with osimertinib±chemo (vs 53% placebo+chemo); MRD clearance 83–84% with osi arms.
Why it matters: Supports MRD as a decision tool and biologic readout in resectable EGFRm disease.
5) MA08.06 — Asandeutertinib vs osimertinib in EGFRm NSCLC with brain mets (interim, 1L)
Signal: Higher intracranial response than osi.
Key data: BICR iORR 91.9% vs 76.1% (P=0.001); INV iORR similar delta; iPFS/PFS NR; more ≥G3 TRAEs and ILD/QT signals with asandeutertinib.
Why it matters: A potential CNS-optimized TKI challenger; safety profile will be key.
6) OA08.04 — SHERLOCK: Sotorasib + bevacizumab + carbo/pem (1L KRAS G12C)
Signal: High responses across PD-L1 and co-mutations.
Key data: Confirmed ORR 62%; median PFS 9.0 mo; KRAS G12C ctDNA clearance 84–95% by week 8–16; intracranial responses in 30% (non-target lesions).
Why it matters: Supports moving G12C inhibitors up front in rational triplets.
7) MA10.09 — EMPOWER-Lung 3 (cemiplimab+chemo) 5-year update
Signal: Durable survival with I/O+chemo.
Key data: Median OS 21.1 vs 12.9 mo (HR 0.66); 5-yr OS 19.4% vs 8.8%; benefit in both Sq and NSq.
Why it matters: Long-tail survival confirmation strengthens first-line I/O+chemo standard.
8) OA02.03 — CheckMate 816 (neoadjuvant nivo+chemo) final 5-year OS by surgery
Signal: Long-term survival advantage in those reaching surgery.
Key data: 5-yr OS 74% vs 63% with definitive surgery; benefit across surgical approaches and R0 status.
Why it matters: Enduring value of neoadjuvant chemo-I/O in resectable NSCLC.
9) OA05.01 — ASTRUM-002: 1L serplulimab+chemo ± bevacizumab (nsNSCLC)
Signal: PD-1+chemo beats chemo; adding bev shows numerical (not significant) PFS gain.
Key data: PFS 11.0 vs 5.6 mo (HR 0.55) for PD-1+chemo vs chemo; with bev: 12.6 vs 11.0 mo (HR 0.86, NS).
Why it matters: Confirms PD-1+chemo baseline; bev add-on benefit remains uncertain here.
10) OA05.02 — IFCT-1805 Elderly: Atezolizumab+chemo in ≥70 years (1L)
Signal: PFS/ORR benefit; OS neutral with more ≥G3 AEs.
Key data: PFS 7.4 vs 5.7 mo (HR 0.56); ORR 51% vs 42%; OS 18.6 vs 15.0 mo (NS); higher ≥G3 TRAEs and serious AEs with I/O.
Why it matters: Nuanced risk-benefit in older adults; supports individualized decisions.
“On Deck” (Embargoed Plenaries — reveal during session)
PL02.06 — FLAURA2 Final OS: Osimertinib+chemo vs osi monotherapy in EGFRm aNSCLC (final OS).
PL02.09 — ACROSS-2: Aumolertinib+chemo for EGFR with co-mutated tumor suppressors.
PL02.12 — HARMONi: Ivonescimab + chemo after progression on 3rd-gen EGFR-TKI.
I’ll post quick takes for each as the embargo lifts.